Erneute Anti-HER2-Therapie mit Herceptin® beim ersten Rezidiv des HER2-positiven Mammakarzinoms-1. Interimsanalyse der nichtinterventionellen Studie (NIS) ML21589. 2. Juni 2012 Hanker, L., Prange-Krex, G., Janssen, J., Reichert, D., Schröder, J., Förster, F., Schnohr, S., Hitschold, T., Indorf, M., Kaufmann, M., 2012. Senologie 9(02). doi:10.1055/s-0032-1313426 Abstract Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Hadji, P., Kieback, D.G., Tams, J., Hasenburg, A., Ziller, M., 2012. Ann Oncol 23, 2566–2572. doi:10.1093/annonc/mds055. Abstract… Weiterlesen Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab? Hartmann, H., Müller, J., Marschner, N., 2012. J Clin Oncol 30, 3317–3318. doi:10.1200/JCO.2012.43.3409 Abstract… Weiterlesen